Was It A Good Call? NVO and Major Pharmeuticals

I published my very first Seeking Alpha article on January 9th, 2017.

I looked at 11 companies classified as Major Pharmaceuticals:

PFE
AZN
NVO
LLY
GSK
BMY
ABBV
SNY
NVS
MRK
JNJ

I concluded that NVO was the best choice as it was undervalued, had high quality earnings and five years of year over year growth in earnings.

How did that call do, roughly 3.5 years later?

We've added a new feature to INVRS called Performance Graphs. Let's take a look:

The green bar shows the average return for the group, the purple annualizes it and the blue divides adjusts the return for risk by dividing it by its standard deviation.

Clicking into the "All Securities" at the bottom breaks the group into its parts. NVO wasn't the best. It was third from a return perspective and second from a risk adjusted perspective. It was double the group average.

LLY and AZN, based on my method of analysis did not have anything to recommend them. They weren't in the running.

I'm pleased with the result. AZN would have been the best call, maybe of the three (it also has the best dividend yield), but NVO still did really well.

Just for fits and wiggles, here a graph of the S&P 500 plus a couple of S&P Health Care indices.

The S&P, over the save 3.5 year time period went up 34%.

What are your thoughts?

Comments

11 Reasons Why INVRS is Better Than Excel Alone

If you work with your own investment models you likely use excel to build them, but excel isn’t ideal for many reasons and it costs you in other ways. First, you need good data and it isn’t just lying around in an easy to import format. You’re either keying it in yourself or paying money for excel downloads. When you need data from numerous sources – price information, data from different statements and across multiple years - you must merge it from multiple sheets. It's a n inefficient process which can lead to data corruption. After all this data is collected and merged, models built and tested, the net result is one statistic for one company. A stand-alone number without context has limited use. To be meaningful, you need to compare it to similar companies. This is just a sample of the challenges. You need software that overcomes these problems and is designed for investment model creation. Surprise! This software exists,

NextEra - Good Dividend in the Renewable Energy Sector

NextEra had good results relative to a group of peers in a factor-based analysis. NextEra has an appealing profitability and income profile. Its price momentum looks decent, with a caveat. Its relatively small size (a small mid-cap) coupled with its industry (renewable energy) further weight the odds that this company could be a strong performer in the future. If you want in on renewable energy, we recommend NextEra. The Analysis Overview I created a portfolio of stocks in the alternative energy sector, looking specifically for companies with a market cap over $1B but less than $4B. This is a sweet spot that offers strong potential for growth but is also substantial enough not to be too speculative. It's my believe that alternative energy is on the ascendance, where as fossil fuels will inevitably decline (NextEra isn't a pure play in this regard however, natural gas assets are part of its portfolio). If you share this belief and you want exposure to this ma

GlaxoSmithKline Scores High in Quality

I created a portfolio of the top pharmaceutical companies trading in the US and ran a quality of earnings analysis on them. With the highest possible score being nine, GSK scored the best with seven. Here are the results: Quality of Earnings - Major Pharmaceuticals Here's the balance of the companies in the portfolio. We can see that AZN was the worst at two. Quality of Earnings - Major Pharmaceuticals 2 Just for laughs, lets see how GSK and AZN have performed from a price perspective. Interestingly, AZN has been outperforming GSK. It'll be interesting to say if this trend will continue or if it will, more correctly I believe, reverse.

The INVRS Blog

Search This Blog